{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "TRVI",
  "name": "Trevi Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/TRVI/",
  "json_url": "https://orbyd.app/dossiers/TRVI.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional marketing rather than data. Consensus PT $24.90 vs 10 Strong Buys still sits above spot; the Aug 6 Q2 print is the only dated event before a 14-month data desert.",
  "invalidation_trigger": "A weekly close below $16 surrenders the June breakout shelf over the prior $16.12 52-week high and returns the name to its $13–16 post-offering cage. Secondary: an 8-K disclosing a Phase 3 clinical hold, protocol amendment or SAE cluster, or a fresh equity raise into strength despite guided runway into 2030.",
  "catalyst_date": "2026-08-06",
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-06-12",
  "invalidation_fired": false,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Single-asset binary (Haduvio / oral nalbuphine ER) — cap speculative sizing at ~1.5% even on a bullish trigger; a Phase 3 miss in 2027-2028 is a 60-80% drawdown scenario",
    "CORRECTION carried forward: the major de-risking event is BEHIND this name. CORAL Phase 2b (IPF chronic cough) read out positive 2025-06-02 (60.2% 24h cough reduction at 108mg BID, p<0.0001, placebo-adj -43.3%, n=165), published JAMA Jan 2026. RIVER was the earlier Phase 2a refractory chronic cough trial, NOT a 2026 catalyst.",
    "Catalyst desert: next efficacy topline is Phase 3 Trial 2 in H2 2027; first Phase 3 IPF trial (Trial 1) topline guided H1 2028. Only readable interim is the RCC Phase 2b sample-size re-estimation guided Q4 2026.",
    "Dilution machinery armed: 2026-06-03 shareholders doubled authorized shares 200M->400M and added 8M to the incentive plan. A raise into this strength would be the warning shot, not the runway.",
    "Balance sheet: Q1-end (Mar 31) cash and marketable securities $171.8M; pro forma ~$334M including April net proceeds of ~$162M; runway guided into 2030 (reported 2026-05-05).",
    "High beta to XBI — do not initiate on sector-driven moves with no TRVI-specific news.",
    "Market cap re-rated to $2.71B on 141.98M shares at $19.07 (2026-07-17) — the small-cap asymmetry that existed at $6.55 is largely spent; this is now a mid-cap priced for Phase 3 success.",
    "Stifel Buy PT $18 was already exceeded by spot on 2026-07-17 — watch for PT raises (confirmation) vs downgrades-to-hold on valuation (distribution signal)."
  ],
  "body_markdown": "## Current Thesis\nThe June breakout was not a one-off. After clearing the old $16.12 52-week high in late June and printing an $18.17 all-time high, Trevi extended again in mid-July: a +9.85% session on July 17, 2026 closed at $19.07 with 8.3M shares traded and an intraday print of $20.22. That is roughly +45% in six weeks and near +240% over twelve months, against a 52-week low of $6.55. Market capitalisation is now $2.71B on 141.98M shares.\n\nWhat an investor is buying at this level is the only clean shot at IPF-related chronic cough — an indication with no approved therapy — now FDA-aligned, funded through approval, and entering its pivotal phase. The complication is what is fuelling the current leg. The advance runs on Phase 3 launch mechanics, conference visibility (BIO International June 22–25, Leerink, ERS Cough Conference), and institutional marketing: management met large funds in London on July 14 in a Cantor Fitzgerald non-deal roadshow. No fresh efficacy data has printed since CORAL in June 2025. The first Phase 3 topline (Trial 2, 12-week dosing) is guided to H2 2027; the lead trial reads H1 2028. Sell-side has not faded the move — 10 analysts carry a Strong Buy consensus with an average target near $24.90 and a $20–30 range — but Stifel's $18 target was overtaken by spot on July 17, which is the shape a re-rating takes right before targets either get raised or the ratings go stale.\n\n## Bull Case\n- Second breakout leg confirmed: shares cleared the $18.17 June all-time high and touched $20.22 on July 17, 2026, closing +9.85% at $19.07 on 8.3M shares — expansion in both price and volume, not a drift.\n- Efficacy already de-risked once: CORAL Phase 2b (topline June 2, 2025, n=165) cut 24-hour cough frequency 60.2% / 53.4% / 47.9% across three doses versus 16.9% on placebo, p<0.0001 at the top two doses, published in JAMA in January 2026.\n- Regulatory path locked: the March 9, 2026 End-of-Phase 2 meeting produced FDA alignment on a two-trial pivotal program — Trial 1 (~300 patients, 52-week dosing, primary endpoint at 24 weeks) initiating Q2 2026, Trial 2 (~130 patients, 12-week dosing) in H2 2026, both at 54mg BID, 2:1 randomisation, objective 24-hour cough frequency as primary.\n- Competitive void intact: no approved therapy exists for IPF-related chronic cough, and Merck's gefapixant (P2X3) drew a CRL, leaving nalbuphine's kappa-agonist/mu-antagonist mechanism uncontested in the indication.\n- Funded past the binary: Q1-end cash and marketable securities of $171.8M plus ~$162M net from the April raise put pro forma cash near $334M, with runway guided into 2030 — through both Phase 3 initiations and toward a potential filing.\n- IP extended: a notice to grant a European patent covering nalbuphine ER in IPF-related chronic cough runs to 2039.\n- Street still above spot: consensus target $24.90 across 10 analysts (7 buys, 0 holds, 0 sells), high forecast $30.00.\n\n## Bear Case\n- The leg has no data underneath it. Trial initiation, conference slots, and a roadshow are marketing events. The next efficacy topline is fourteen months out at the earliest, and \"initiation\" press releases have a long history of being sold once printed.\n- Extension is real: $19.07 sits ~18% above the old $16.12 resistance and ~47% above the $13.00 April offering clear, after a near-vertical six-week run. Every buyer above $18 is underwater on any give-back to the breakout shelf.\n- The asymmetry has been spent. At $6.55 this was a lottery ticket; at $2.71B it is priced for Phase 3 success in an indication where no drug has ever been approved. A miss in 2027–2028 is a 60–80% drawdown on standard single-asset math.\n- Dilution capacity is armed. Shareholders doubled authorised shares 200M→400M on June 3, 2026 and added 8M to the incentive plan. Runway into 2030 does not stop an opportunistic raise into a doubled tape — it makes one easier.\n- Burn is climbing into pivotal spend: Q1 2026 net loss $13.2M versus $10.3M a year earlier, trailing net income -$45.61M, EPS -$0.32.\n- High beta to XBI. With no company-specific driver for over a year, the tape becomes a sector-flow proxy, and sector flows reverse without warning.\n- Stifel's $18 target now sits below the market price. A valuation-based downgrade would land on a stock with no data to rebut it.\n\n## Setup & Price Structure\nStructure is clean and stretched at the same time. The $13–16 post-offering cage held from April into mid-June; the June 27 break through $16.12 established the shelf, and $18.17 became the marker until July 17 took it out. The relevant levels descend in order: $18.17 (June all-time high, now first support), $16.12 (breakout shelf and the line that defines the trend), $13.00 (April offering clear, structural floor). A weekly close beneath $16 is what returns the name to the cage.\n\nThe name is a long way above any short-term moving average after two consecutive expansion legs, and momentum readings are at the upper end of their range. In an accelerating narrative that is confirmation rather than a sell signal — nothing about the setup is broken. That geometry argues for a small, position-sized probe rather than conviction sizing, regardless of how strong the tape looks.\n\n## Catalyst Calendar (next 30 days)\n\n- **Undated, Q3-window** — Phase 3 Trial 2 (~130 patients, 12-week dosing) initiation, guided to H2 2026. Operational PR, not data.\n- **~Q4 2026** — RCC Phase 2b sample-size re-estimation readout. The only interim signal on enrollment and effect before the 2027 toplines. Outside the 30-day window but the next thing that actually matters.\n- No efficacy topline, PDUFA, or advisory-committee date exists in this window. Anything that moves the stock in the next 30 days is flow, sell-side action, or the August print.\n\n## Elapsed catalysts\n\n- **2026-08-06** — Q2 2026 financial results and corporate update. The operative event: Phase 3 Trial 1 enrollment status, confirmation the second Phase 3 initiated or is on track for H2 2026, RCC Phase 2b progress, and updated cash. Avoid fresh entries in the three sessions ahead of the print. *(passed 3d ago)*\n- **~2026-08-06 (with the Q2 filing)** — 10-Q. Watch for any ATM activity or shelf usage disclosure following the June authorised-share increase. *(passed 3d ago)*\n\n## What Would Change Our Mind\n- A weekly close below $16 — the breakout shelf over the prior $16.12 high is gone and the $13–16 range reasserts. A daily close below $13 confirms a structural break back to the offering anchor.\n- Any 8-K disclosing a Phase 3 clinical hold, protocol amendment, dose change off 54mg BID, or an SAE cluster. Nalbuphine's tolerability profile (nausea, dizziness, discontinuations) is the known soft spot; a discontinuation-driven amendment reprices the whole program.\n- An equity raise despite guided runway into 2030. The June authorisation increase is the enabling mechanism; using it into strength signals management sees this price as the opportunity, and caps multiple expansion.\n- Slippage on the second Phase 3 initiation past 2026, or an August print that describes Trial 1 enrollment as slower than planned — the timeline is the only thing holding the narrative together in a data desert.\n- Sell-side downgrades on valuation with targets cut toward spot, particularly if paired with distribution volume on down days.\n- Conversely, upside confirmation would be target raises above $30 on the August print with enrollment ahead of plan, or a partnership/licensing structure that de-risks the single-asset exposure.\n\n## Correlation Notes\n- Tightly coupled to XBI and small/mid-cap biotech risk appetite. With no idiosyncratic driver for roughly fourteen months, sector beta dominates day-to-day behaviour; entries on XBI-driven strength with no TRVI news are entries into noise.\n- Rate-sensitive in the standard clinical-stage way — long-duration cash flows, zero revenue. A hawkish repricing hits this cohort before it hits anything with earnings.\n- Read-across from the IPF/pulmonary complex: anti-fibrotic and chronic-cough peers (Merck's P2X3 program history, Bellus/GSK camlipixant, IPF-adjacent readouts) shape sentiment on the indication's commercial ceiling even without touching Trevi's own data.\n- Ownership is specialist-heavy — Concentrated healthcare-fund ownership makes the name gap harder in both directions on redemption-driven flows.\n- Float dynamics: 141.98M shares outstanding with 8.3M traded on July 17 shows genuine liquidity now, so the squeeze characteristics that marked earlier moves are diminished — this trades as an institutional re-rating, and the risk is institutional exit.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-07-19T11:53:13+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}